-
EP2934603
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2934603
| EP2934603 - VIRAL INACTIVATED BIOLOGICAL MIXTURE [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 03.09.2021 Database last updated on 28.03.2026 | |
| Former | Grant of patent is intended Status updated on 15.12.2020 | ||
| Former | Examination is in progress Status updated on 23.12.2016 | Most recent event Tooltip | 03.09.2021 | Application deemed to be withdrawn | published on 06.10.2021 [2021/40] | Applicant(s) | For all designated states Omrix Biopharmaceuticals Ltd. Bldg.14 Weizmann Science Park P.O. Box 619 Rehovot 76106 / IL | [2015/44] | Inventor(s) | 01 /
WEISSMAN, Lior 13b Alon Street 7420917 Nes-Ziona / IL | 02 /
PODOLER, Itai Mohaliver 2/10 7630415 Rehovot / IL | 03 /
BYK-TENNENBAUM, Tamara 12 Hahaganah Street 5527809 Kiryat Ono / IL | 04 /
NUR, Israel House No. 277 7986000 Moshav Timmorim / IL | [2015/44] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2015/44] | Application number, filing date | 13821991.0 | 19.12.2013 | [2015/44] | WO2013IL00096 | Priority number, date | US201261740140P | 20.12.2012 Original published format: US 201261740140 P | IL20120223786 | 20.12.2012 Original published format: IL 22378612 | [2015/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014097289 | Date: | 26.06.2014 | Language: | EN | [2014/26] | Type: | A1 Application with search report | No.: | EP2934603 | Date: | 28.10.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.06.2014 takes the place of the publication of the European patent application. | [2015/44] | Search report(s) | International search report - published on: | EP | 26.06.2014 | Classification | IPC: | A61L2/00 | [2015/44] | CPC: |
A61L2/18 (EP,IL,US);
A61K35/19 (IL,US);
A61K38/1825 (EP,IL,US);
A61K38/1858 (EP,IL,US);
A61L2/00 (EP,IL,US);
A61L2103/05 (EP,IL,US);
A61L2103/09 (EP,IL,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/44] | Title | German: | INAKTIVIERTE VIRALE BIOLOGISCHE MISCHUNG | [2015/44] | English: | VIRAL INACTIVATED BIOLOGICAL MIXTURE | [2015/44] | French: | MÉLANGE BIOLOGIQUE INACTIVÉ VIRAL | [2015/44] | Entry into regional phase | 20.07.2015 | National basic fee paid | 20.07.2015 | Designation fee(s) paid | 20.07.2015 | Examination fee paid | Examination procedure | 20.07.2015 | Examination requested [2015/44] | 14.03.2016 | Amendment by applicant (claims and/or description) | 02.01.2017 | Despatch of a communication from the examining division (Time limit: M04) | 11.05.2017 | Reply to a communication from the examining division | 23.11.2020 | Cancellation of oral proceeding that was planned for 11.12.2020 | 11.12.2020 | Date of oral proceedings (cancelled) | 16.12.2020 | Communication of intention to grant the patent | 27.04.2021 | Application deemed to be withdrawn, date of legal effect [2021/40] | 21.05.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2021/40] | Divisional application(s) | EP21159598.8 / EP3848058 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 02.01.2017 | Fees paid | Renewal fee | 10.12.2015 | Renewal fee patent year 03 | 13.12.2016 | Renewal fee patent year 04 | 12.12.2017 | Renewal fee patent year 05 | 12.12.2018 | Renewal fee patent year 06 | 13.12.2019 | Renewal fee patent year 07 | 14.12.2020 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XA] WO2012085910 (OMRIX BIOPHARMACEUTICALS LTD et al.) | [XA] EP1060741 (EPIC THERAPEUTICS INC et al.) | Examination | WO2008145989 | US5589462 | by applicant | US2012156306 | US5094960 | US4789545 | US6121232 | WO9833533 | US7125569 | WO02095019 | LACCI KM; DARDIK A: "Platelet-rich plasma: support for its use in wound healing", YALE J BIOL MED., vol. 83, no. 1, March 2010 (2010-03-01), pages 1 - 9, XP055059137 | KANNO ET AL.: "Platelet-rich plasma enhances human osteoblast-like cell proliferation and differentiation", J ORAL MAXILLOFAC SURG., vol. 63, no. 3, March 2005 (2005-03-01), pages 362 - 9, XP004760497, DOI: doi:10.1016/j.joms.2004.07.016 DOI: http://dx.doi.org/10.1016/j.joms.2004.07.016 | BERTRAND-DUCHESNE ET AL.: "Epidermal growth factor released from platelet-rich plasma promotes endothelial cell proliferation in vitro", J PERIODONTAL RES., vol. 45, no. 1, February 2010 (2010-02-01), pages 87 - 93 | KAKUDO ET AL.: "Proliferation-promoting effect of platelet-rich plasma on human adipose-derived stem cells and human dermal fibroblasts", PLAST RECONSTR SURG., vol. 122, no. 5, November 2008 (2008-11-01), pages 1352 - 60 | SULPICE ET AL.: "Crosstalk between the VEGF-A and HGF signalling pathways in endothelial cells", BIOL CELL, vol. 101, no. 9, September 2009 (2009-09-01), pages 525 - 39 | RUGHETTI ET AL.: "Platelet gel-released supernatant modulates the angiogenic capability of human endothelial cells", BLOOD TRANSFUS., vol. 6, no. 1, January 2008 (2008-01-01), pages 12 - 7 | INTINI G.: "The use of platelet- ' rich plasma in bone reconstruction therapy", BIOMATERIALS, vol. 30, no. 28, October 2009 (2009-10-01), pages 4956 - 66, XP026420863 | JOHANSSON ET AL.: "Platelet.lysate: a replacement for fetal bovine serum in animal cell culture?", CYTOTECHNOLOGY, vol. 42, no. 2, July 2003 (2003-07-01), pages 67 - 74, XP002396789 | NURDEN ET AL.: "Platelets and wound healing", FRONT BIOSCI., vol. 13, 1 May 2008 (2008-05-01), pages 3532 - 48 | MAZZUCCO ET AL.: "Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure", VOX SANG., vol. 97, no. 2, August 2009 (2009-08-01), pages 110 - 8 | ROZMAN P; BOLTA Z: "Use of platelet growth factors in treating wounds and soft-tissue injuries", ACTA DERMATOVENEROL ALP PANONICA ADRIAT., vol. 16, no. 4, December 2007 (2007-12-01), pages 156 - 65 | SU ET AL.: "A vitally inactivated functional growth factor preparation from human platelet concentrates", VOX SANG., vol. 97, no. 2, August 2009 (2009-08-01), pages 119 - 128, XP055020854, DOI: doi:10.1111/j.1423-0410.2009.01180.x DOI: http://dx.doi.org/10.1111/j.1423-0410.2009.01180.x | BURNOUF ET AL.: "A novel virally inactivated human platelet lysate preparation rich in TGF-beta, EGF and IGF, and depleted of PDGF and VEGF", BIOTECHNOL APPL BIOCHEM., vol. 56, no. 4, 6 August 2010 (2010-08-06), pages 151 - 60, XP009150255 | SLEZAK ET AL., J. EXP. MED., vol. V166, 1987, pages 489 - 505 | SALGANICOFF ET AL., BIOCHEM. BIOPHYS. ACTA, vol. V385, 1975, pages 394 - 411 | GUERRIER 'L ET AL.: "Specific sorbent to remove solvent-detergent mixtures from virus-inactivated biological fluids", J CHROMATOGR B BIOMED APPL., vol. 664, no. 1, 3 February 1995 (1995-02-03), pages 119 - 125, XP004043713, DOI: doi:10.1016/0378-4347(94)00363-A DOI: http://dx.doi.org/10.1016/0378-4347(94)00363-A | CIRCULAR OF INFORMATION FOR THE USE OF HUMAN BLOOD AND BLOOD COMPONENTS, December 2009 (2009-12-01) | EUROPEAN PHARMACOPAIEA ASSAY PROCEDURE, vol. 0903, 1997, pages 858 | GUERRIER L ET AL.: "Specific sorbent to remove solvent-detergent mixtures from virus-inactivated biological fluids", J CHROMATOGR B BIOMED APPL., vol. 664, no. 1, 3 February 1995 (1995-02-03), pages 119 - 125, XP004043713, DOI: doi:10.1016/0378-4347(94)00363-A DOI: http://dx.doi.org/10.1016/0378-4347(94)00363-A | HIRSH; RASCHKE: "Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy", CHEST, vol. 126, 2004, pages 188S - 203S | MACHOVICH R ET AL.: "Effect of Heparin on Thrombin Inactivation by Antithrombin - III", BIOCHEM. J., vol. 173, 1978, pages 869 - 875 | MCFARLANE ET AL., PLAST RECONST SURG, vol. 35, 1965, pages 177 |